CD155 downregulation synergizes with adriamycin to induce breast cancer cell apoptosis.
CD155 has been implicated in migration, invasion, proliferation and apoptosis of human cancer cells, and DNA damage response caused by chemotherapeutic agents or reactive oxygen species has been shown to attribute to CD155 induction. Adriamycin (Adr) is one of the most common chemotherapeutic drugs used to treat breast cancer. Here we reported that treatment with Adr upregulated CD155 expression on several in vitro cultured breast cancer cells and in breast cancer cell 4T1 xenografts. We also found that CD155 knockdown or Adr treatment induced apoptosis of in vitro cultured cancer cells and cancer cells in 4T1 xenografts, and a combination of CD155 knockdown with Adr treatment induced more cell death than either of them. Furthermore, we revealed that the combination of CD155 knockdown with Adr treatment suppressed the growth of 4T1 xenografts more significantly than them alone. In summary, our results demonstrate that CD155 downregulation synergizes with Adr to induce breast cancer cell apoptosis, thereby to suppress tumor growth. Our results also suggest that CD155 upregulation may be a mechanism underlying Adr resistance by breast cancer cells.
['Gao|Jian|J|', 'Zheng|Qianqian|Q|', 'Shao|Yue|Y|', 'Wang|Wei|W|', 'Zhao|Chenghai|C|']
D000818:Animals D017209:Apoptosis D001943:Breast Neoplasms D049109:Cell Proliferation D004249:DNA Damage D004317:Doxorubicin D019008:Drug Resistance, Neoplasm D005260:Female D015972:Gene Expression Regulation, Neoplastic D006801:Humans D061986:MCF-7 Cells D051379:Mice D011991:Receptors, Virus D015398:Signal Transduction D023041:Xenograft Model Antitumor Assays
CD155 Adriamycin Breast cancer Apoptosis